DOCSLIB.ORG

Table S2. Protein Identities Included in PEA Immunoassay No. Protein

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table S2. Protein Identities Included in PEA Immunoassay No. Protein Table S2. Protein identities included in PEA immunoassay No. Protein Biomarkers analyzed by PEA 1 Aminopeptidase N (AP-N) 2 Azurocidin (AZU1 3 Bleomycin hydrolase (BLM hydrolase) 4 C-C motif chemokine 15 (CCL15) 5 C-C motif chemokine 16 (CCL16) 6 C-C motif chemokine 24 (CCL24) 7 C-X-C motif chemokine 16 (CXCL16) 8 Cadherin-5 (CDH5) 9 Carboxypeptidase A1 (CPA1) 10 Carboxypeptidase B (CPB1) 11 Caspase-3 (CASP-3) 12 Cathepsin D (CTSD) 13 Cathepsin Z (CTSZ) 14 CD166 antigen (ALCAM) 15 Chitinase-3-like protein 1 (CHI3L1) 16 Chitotriosidase-1 (CHIT1) 17 Collagen alpha-1(I) chain (COL1A1) 18 Complement component C1q receptor (CD93) 19 Contactin-1 (CNTN1) 20 Cystatin-B (CSTB) 21 E-selectin (SELE) 22 Elafin (PI3) 23 Ephrin type-B receptor 4 (EPHB4) 24 Epidermal growth factor receptor (EGFR ) 25 Epithelial cell adhesion molecule (Ep-CAM) 26 Fatty acid-binding protein, adipocyte (FABP4) 27 Galectin-3 (Gal-3) 28 Galectin-4 (Gal-4) 29 Granulins (GRN) 30 Growth/differentiation factor 15 (GDF-15) 31 Insulin-like growth factor-binding protein 1 (IGFBP-1) 32 Insulin-like growth factor-binding protein 2 (IGFBP-2) 33 Insulin-like growth factor-binding protein 7 (IGFBP-7) 34 Integrin beta-2 (ITGB2) 35 Intercellular adhesion molecule 2 (ICAM-2) 36 Interleukin-1 receptor type 1 (IL-1RT1) 37 Interleukin-1 receptor type 2 (IL-1RT2) 38 Interleukin-17 receptor A (IL-17RA) 39 Interleukin-18-binding protein (IL-18BP) 40 Interleukin-2 receptor subunit alpha (IL2-RA) 41 Interleukin-6 receptor subunit alpha (IL-6RA) 42 Junctional adhesion molecule A (JAM-A) 43 Kallikrein-6 (KLK6 ) 44 Low-density lipoprotein receptor (LDL receptor) 45 Lymphotoxin-beta receptor (LTBR) 46 Matrix extracellular phosphoglycoprotein (MEPE) 47 Matrix metalloproteinase-2 (MMP-2) 48 Matrix metalloproteinase-3 (MMP-3) 49 Matrix metalloproteinase-9 (MMP-9) 50 Metalloproteinase inhibitor 4 (TIMP4) 51 Monocyte chemotactic protein 1 (MCP-1) 52 Myeloblastin (PRTN3) 53 Myeloperoxidase (MPO) 54 Myoglobin (MB) 55 N-terminal prohormone brain natriuretic peptide (NT-proBNP) 56 Neurogenic locus notch homolog protein 3 (Notch 3) 57 Osteopontin (OPN) 58 Osteoprotegerin (OPG) 59 P-selectin (SELP) 60 Paraoxonase (PON3) 61 Peptidoglycan recognition protein 1 (PGLYRP1) 62 Perlecan (PLC) 63 Plasminogen activator inhibitor 1 (PAI) 64 Platelet endothelial cell adhesion molecule (PECAM-1) 65 Platelet-derived growth factor subunit A (PDGF subunit A) 66 Proprotein convertase subtilisin/kexin type 9 (PCSK9) 67 Protein delta homolog 1 (DLK-1) 68 Pulmonary surfactant-associated protein D (PSP-D) 69 Resistin (RETN) 70 Retinoic acid receptor responder protein 2 (RARRES2) 71 Scavenger receptor cysteine-rich type 1 protein M130 (CD163) 72 Secretoglobin family 3A member 2 (SCGB3A2) 73 Spondin-1 (SPON1) 74 ST2 protein (ST2) 75 Tartrate-resistant acid phosphatase type 5 (TR-AP) 76 Tissue factor pathway inhibitor (TFPI) 77 Tissue-type plasminogen activator (t-PA) 78 Transferrin receptor protein 1 (TR) 79 Trefoil factor 3 (TFF3) 80 Trem-like transcript 2 protein (TLT-2) 81 Tumor necrosis factor ligand superfamily member 13B (TNFSF13B) 82 Tumor necrosis factor receptor 1 (TNF-R1) 83 Tumor necrosis factor receptor 2 (TNF-R2) 84 TNFR superfamily member 10C (TNFRSF10C) 85 Tumor necrosis factor receptor superfamily member 14 (TNFRSF14) 86 Tumor necrosis factor receptor superfamily member 6 (FAS ) 87 Tyrosine-protein kinase receptor UFO (AXL) 88 Tyrosine-protein phosphatase non-receptor type substrate 1 (SHPS-1) 89 Urokinase plasminogen activator surface receptor (U-PAR) 90 Urokinase-type plasminogen activator (uPA) 91 von Willebrand factor (vWF) 92 5'-nucleotidase (5'-NT) 93 ADAM-TS 15 94 Alpha-taxilin (TXLNA) 95 Amphiregulin (AREG) 96 Annexin A1 (ANXA1) 97 C-type lectin domain family 4 member K (CD207) 98 C-X-C motif chemokine 13 (CXCL13 ) 99 Carbonic anhydrase IX (CAIX) 100 Carboxypeptidase E (CPE) 101 Carcinoembryonic antigen (CEA) 102 CEACAM1 103 Cathepsin L2 (CTSV) 104 CD160 antigen (CD160) 105 CD27 antigen (CD27) 106 CD48 antigen (CD48) 107 CD70 antigen (CD70) 108 Cornulin (CRNN) 109 Cyclin-dependent kinase inhibitor 1 (CDKN1A) 110 Delta-like protein 1 (DLL1) 111 ADAM8 112 Endothelial cell-specific molecule 1 (ESM-1) 113 Ephrin type-A receptor 2 (EPHA2) 114 Fas antigen ligand (FasL) 115 FAS-associated death domain protein (FADD) 116 Fc receptor-like B (FCRLB) 117 Fibroblast growth factor-binding protein 1 (FGF-BP1) 118 Folate receptor alpha (FR-alpha) 119 Folate receptor gamma (FR-gamma) 120 Furin (FUR) 121 Galectin-1 (Gal-1) 122 Glypican-1 (GPC1) 123 Granzyme B (GZMB) 124 Granzyme H (GZMH) 125 Hepatocyte growth factor (HGF) 126 ICOS ligand (ICOSLG) 127 Insulin-like growth factor 1 receptor (IGF1R) 128 Integrin alpha-V (ITGAV) 129 Integrin beta-5 (ITGB5) 130 Interferon gamma receptor 1 (IFN-gamma-R1) 131 Interleukin-6 (IL6) 132 Kallikrein-11 (hK11) 133 Kallikrein-13 (KLK13) 134 Kallikrein-14 (hK14) 135 Kallikrein-8 (hK8) 136 Ly6/PLAUR domain-containing protein 3 (LYPD3) 137 Melanoma-derived growth regulatory protein (MIA) 138 Mesothelin (MSLN) 139 Methionine aminopeptidase 2 (MetAP 2) 140 MHC class I polypeptide-related sequence A/B (MIC-A/B) 141 Midkine (MK) 142 Mothers against decapentaplegic homolog 5 (MAD homolog 5) 143 Mucin-16 (MUC-16) 144 Nectin-4 (PVRL4) 145 Pancreatic prohormone (PPY) 146 Podocalyxin (PODXL) 147 Pro-epidermal growth factor (EGF) 148 Protein CYR61 (CYR61) 149 Protein S100-A11 (S100A11) 150 Protein S100-A4 (S100A4) 151 Proto-oncogene tyrosine-protein kinase receptor Ret (RET) 152 R-spondin-3 (RSPO3) 153 Receptor tyrosine-protein kinase erbB-2 (ErbB2/HER2) 154 Receptor tyrosine-protein kinase erbB-3 (ErbB3/HER3) 155 Receptor tyrosine-protein kinase erbB-4 (ErbB4/HER4) 156 Secretory carrier-associated membrane protein 3 (SCAMP3) 157 Seizure 6-like protein (SEZ6L) 158 SPARC (SPARC) 159 Stem cell factor (SCF) 160 Syndecan-1 (SYND1) 161 T-cell leukemia / lymphoma protein 1A (TCL1A) 162 T-lymphocyte surface antigen Ly-9 (LY9) 163 TGF-beta receptor type-2 (TGFR-2) 164 Tissue factor pathway inhibitor 2 (TFPI-2) 165 TNF-related apoptosis-inducing ligand (TRAIL) 166 Toll-like receptor 3 (TLR3) 167 Transforming growth factor alpha (TGF-alpha) 168 Transmembrane glycoprotein NMB (GPNMB) 169 Tumor necrosis factor ligand superfamily member 13 (TNFSF13) 170 Tumor necrosis factor receptor superfamily member 19 (TNFRSF19) 171 Tumor necrosis factor receptor superfamily member 4 (TNFRSF4 ) 172 Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B) 173 Tyrosine-protein kinase ABL1 (ABL1) 174 Tyrosine-protein kinase Lyn (LYN) 175 Vascular endothelial growth factor A (VEGF-A) 176 Vascular endothelial growth factor receptor 2 (VEGFR-2) 177 Vascular endothelial growth factor receptor 3 (VEGFR-3) 178 VEGF-co regulated chemokine 1 (CXCL17) 179 Vimentin (VIM) 180 WAP four-disulfide core domain protein 2 (WFDC2) 181 Wnt inhibitory factor 1 (WIF-1) 182 WNT1-inducible-signaling pathway protein 1 (WISP-1) 183 Xaa-Pro aminopeptidase 2 (XPNPEP2) .
Load more

Recommended publications
  • DS Human IL-18
    ® MSD Human IL-18 Kit For quantitative determination in human serum, plasma, and tissue culture supernatants Alzheimer’s Disease IL-18 BioProcess Cardiac Cell Signaling Clinical Immunology Cytokines Growth Factors Hypoxia Immunogenicity Inflammation Metabolic Oncology Interleukin-18 (IL-18) is an 18 kDa cytokine and a co-stimulatory factor that is produced in Kuppfer cells, activated macrophages, Toxicology keratinocytes, and intestinal epithelial cells.1 One of the main functions of IL-18 is to promote the production of IFN-γ from T and NK Vascular cells, particularly in the presence of IL-12p70. IL-18 also promotes the secretion of other proinflammatory cytokines like TNF-α, IL-1β, 2 and GM-CSF that enhance the migration and activtion of neutrophils during microbial infections. IL-18 enhances cytotoxic activity and 2,3 Catalog Numbers proliferation of CD8+ T and NK cells and has been shown to stimulate the production of IL-13 and other Th2 cytokines. Dysregulation of IL-18 may therefore contribute to inflammatory-associated disorders, unchecked infections, autoimmune diseases such as 2,3 Human IL-18 Kit rheumatoid arthritis, acute and chronic kidney injury, cancer, and pathogenic conditions related to metabolic syndrome. Kit size The MSD Human IL - 18 assay is available on 96-well 4-spot plates. This datasheet outlines the performance of the assay. 1 plate K151MCD-1 5 plates K151MCD-2 Assay Sensitivity 25 plates K151MCD-4 IL-18 LLOD (pg/mL) 0.71 The lower limit of detection (LLOD) is a calculated concentration based on a signal Ordering information 2.5 standard deviations above the background (zero calibrator blank).
    [Show full text]
  • Serum Level of Cathepsin B and Its Density in Men with Prostate Cancer As Novel Markers of Disease Progression
    ANTICANCER RESEARCH 24: 2573-2578 (2004) Serum Level of Cathepsin B and its Density in Men with Prostate Cancer as Novel Markers of Disease Progression HIDEAKI MIYAKE1, ISAO HARA2 and HIROSHI ETO1 1Department of Urology, Hyogo Medical Center for Adults, 13-70 Kitaohji-cho, Akashi; 2Department of Urology, Kobe University School of Medicine, 7-5-1 Kusunoki-cho, Kobe, Japan Abstract. Background: Cathepsin B has been shown to play in men in Western industrialized countries and is the second an important role in invasion and metastasis of prostate leading cause of cancer-related death (1). Recent cancer. The objective of this study was to determine whether progression in the fields of diagnosis and follow-up using serum levels of cathepsin B and its density (cathepsin B-D) prostate-specific antigen (PSA) and its associated could be used as predictors of disease extension as well as parameters have contributed to early detection and accurate prognosis in patients with prostate cancer. Materials and prediction of prognosis (2, 3). However, despite these Methods: Serum levels of cathepsin B in 60 healthy controls, advances, more than 50% of patients still show evidence of 80 patients with benign prostatic hypertrophy (BPH) and 120 advanced disease at the time of diagnosis, and the currently patients with prostate cancer were measured by a sandwich available parameters are not correlated with the clinical enzyme immunoassay. Cathepsin B-D was calculated by course in some patients during progression to hormone- dividing the serum levels of cathepsin B by the prostate refractory disease (4); hence, there is a pressing need to volume, which was measured using transrectal ultra- develop a novel diagnostic and monitoring marker system sonography.
    [Show full text]
  • And Peptide Sequences (>95 % Confidence) in the Non-Raft Fraction
    Supplementary Table 1: Protein identities, their probability scores (protein score and expect score) and peptide sequences (>95 % confidence) in the non-raft fraction. Protein name Protein score Expect score Peptide sequences Glial fibrillary acidic protein 97 0.000058 LALDIEIATYR 0.0000026 LALDIEIATYR Phosphatidylinositol 3-kinase 25 0.038 HGDDLR Uveal autoantigen with coiled-coil domains and ankyrin repeats protein 30 0.03 TEELNR ADAM metallopeptidase domain 32 347 0.0072 SGSICDK 0.0059 YTFCPWR 0.00028 CSEVGPYINR 0.0073 DSASVIYAFVR 0.00044 DSASVIYAFVR 0.00047 LICTYPLQTPFLR 0.0039 LICTYPLQTPFLR 0.001 LICTYPLQTPFLR 0.0000038 AYCFDGGCQDIDAR 0.00000043 AYCFDGGCQDIDAR 0.0000042 VNQCSAQCGGNGVCTSR 0.0000048 NAPFACYEEIQSQTDR 0.000019 NAPFACYEEIQSQTDR Alpha-fetoprotein 24 0.0093 YIYEIAR Junction plakoglobin 214 0.011 ATIGLIR 0.0038 LVQLLVK 0.000043 EGLLAIFK 0.00027 QEGLESVLK 0.000085 TMQNTSDLDTAR 0.000046 ALMGSPQLVAAVVR 0.01 LLNQPNQWPLVK 0.01 NEGTATYAAAVLFR 0.004 NLALCPANHAPLQEAAVIPR 0.0007 VLSVCPSNKPAIVEAGGMQALGK 0.00086 ILVNQLSVDDVNVLTCATGTLSNLTCNNSK Catenin beta-1 54 0.000043 EGLLAIFK Lysozyme 89 0.0026 STDYGIFQINSR 0.00051 STDYGIFQINSR 1 0.0000052 STDYGIFQINSR Annexin A2 72 0.0036 QDIAFAYQR 72 0.0000043 TNQELQEINR Actin, cytoplasmic 61 0.023 IIAPPER 0.021 IIAPPER 0.0044 AGFAGDDAPR 0.013 EITALAPSTMK 0.0013 LCYVALDFEQEMATAASSSSLEK 0.023 IIAPPER 0.021 IIAPPER 0.0044 AGFAGDDAPR 0.0013 LCYVALDFEQEMATAASSSSLEK 0.023 IIAPPER 0.021 IIAPPER 0.0044 AGFAGDDAPR 0.013 EITALAPSTMK ACTA2 protein 35 0.0044 AGFAGDDAPR 0.013 EITALAPSTMK Similar to beta actin
    [Show full text]
  • Expression of the Alpha, Beta, and Gamma Subunits of the Interleukin-2
    Expression of the Alpha, Beta, and Gamma Subunits of the Interleukin-2 Receptor by Human Vascular Smooth Muscle Cells A thesis submitted in partial fulfillment Of the requirements for the degree of Master of Science By Sultan Alhayyani B.S. King Abdulaziz University 2014 Wright State University WRIGHT STATE UNIVERSITY SCHOOL OF GRADUATE STUDIES April 14, 2014 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY SULTAN ALHAYYANI ENTITLED EXPRESSION OF THE ALPHA, BETA, AND GAMMA SUBUNITS OF THE INTERLEUKIN-2 RECEPTOR BY HUMAN VASCULAR SMOOTH MUSCLE CELLS BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science. Lucile Wrenshall, MD, Ph.D. Thesis Director Committee on Final Examination Lucile Wrenshall, MD, Ph.D. Barbara E. Hull, Ph.D. Professor of Neuroscience, Cell Biology, and Director of Microbiology and Physiology Immunology Program, College of Science and Mathematics Barbara E. Hull, Ph.D. Professor of Biological Sciences Nancy J. Bigley, Ph.D. Professor of Microbiology and Immunology John Miller, Ph.D. Adjunct Assistant Professor Of Neuroscience, Cell Biology, and Physiology Robert E. W. Fyffe, Ph.D. Vice President of Research and Dean of the Graduate School ABSTRACT Alhayyani, Sultan. M.S. Microbiology and Immunology Graduate Program, Wright State University, 2014. Expression of the Alpha, Beta, and Gamma Subunits of the Interleukin-2 Receptor by Human Vascular Smooth Muscle Cells. Interleukin 2 (IL-2) is a member of the cytokine family and contributes to the proliferation, survival, and death of lymphocytes [1]. The interleukin-2 receptor (IL-2) is a tripartite receptor commonly expressed on the surfaces of many lymphoid cells and is composed of three non-covalently associated subunits, alpha (α) (CD25), beta (β) (CD122), and gamma (γ) (CD132) [2].
    [Show full text]
  • Role of Interleukin 36Γ in Host Defense Against Tuberculosis Fadhil Ahsan,1,2,A Pedro Moura-Alves,1,A Ute Guhlich-Bornhof,1 Marion Klemm,1 Stefan H
    The Journal of Infectious Diseases MAJOR ARTICLE Role of Interleukin 36γ in Host Defense Against Tuberculosis Fadhil Ahsan,1,2,a Pedro Moura-Alves,1,a Ute Guhlich-Bornhof,1 Marion Klemm,1 Stefan H. E. Kaufmann,1 and Jeroen Maertzdorf1 Downloaded from https://academic.oup.com/jid/article-abstract/214/3/464/2577344 by Deutsches Rheumaforschungs Zentrum user on 26 June 2019 1Department of Immunology, Max Planck Institute for Infection Biology, and 2ZIBI Graduate School Berlin, Germany Tuberculosis remains a major killer worldwide, not the least because of our incomplete knowledge of protective and pathogenic immune mechanism. The roles of the interleukin 1 (IL-1) and interleukin 18 pathways in host defense are well established, as are their regulation through the inflammasome complex. In contrast, the regulation of interleukin 36γ (IL-36γ), a recently described member of the IL-1 family, and its immunological relevance in host defense remain largely unknown. Here we show that Myco- bacterium tuberculosis infection of macrophages induces IL-36γ production in a 2-stage-regulated fashion. In the first stage, mi- crobial ligands trigger host Toll-like receptor and MyD88-dependent pathways, leading to IL-36γ secretion. In the second stage, endogenous IL-1β and interleukin 18 further amplify IL-36γ synthesis. The relevance of this cytokine in the control of M. tuber- culosis is demonstrated by IL-36γ–induced antimicrobial peptides and IL-36 receptor–dependent restriction of M. tuberculosis growth. Thus, we provide first insight into the induction and regulation of the proinflammatory cytokine IL-36γ during tuberculosis. Keywords. IL-36γ; Mycobacterium tuberculosis; TLR; inflammasome; antimicrobial peptide.
    [Show full text]
  • ALCAM Regulates Mediolateral Retinotopic Mapping in the Superior Colliculus
    15630 • The Journal of Neuroscience, December 16, 2009 • 29(50):15630–15641 Development/Plasticity/Repair ALCAM Regulates Mediolateral Retinotopic Mapping in the Superior Colliculus Mona Buhusi,1 Galina P. Demyanenko,1 Karry M. Jannie,2 Jasbir Dalal,1 Eli P. B. Darnell,1 Joshua A. Weiner,2 and Patricia F. Maness1 1Department of Biochemistry and Biophysics, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, and 2Department of Biology, University of Iowa, Iowa City, Iowa 52242 ALCAM [activated leukocyte cell adhesion molecule (BEN/SC-1/DM-GRASP)] is a transmembrane recognition molecule of the Ig superfamily (IgSF) containing five Ig domains (two V-type, three C2-type). Although broadly expressed in the nervous and immune systems, few of its developmental functions have been elucidated. Because ALCAM has been suggested to interact with the IgSF adhesion molecule L1, a determi- nant of retinocollicular mapping, we hypothesized that ALCAM might direct topographic targeting to the superior colliculus (SC) by serving as a substrate within the SC for L1 on incoming retinal ganglion cell (RGC) axons. ALCAM was expressed in the SC during RGC axon targeting and on RGC axons as they formed the optic nerve; however, it was downregulated distally on RGC axons as they entered the SC. Axon tracing with DiI revealedpronouncedmistargetingofRGCaxonsfromthetemporalretinahalfofALCAMnullmicetoabnormallylateralsitesinthecontralateral SC, in which these axons formed multiple ectopic termination zones. ALCAM null mutant axons were
    [Show full text]
  • Newly Developed Serine Protease Inhibitors Decrease Visceral Hypersensitivity in a Post-Inflammatory Rat Model for Irritable Bowel Syndrome
    This item is the archived peer-reviewed author-version of: Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome Reference: Ceuleers Hannah, Hanning Nikita, Heirbaut Leen, Van Remoortel Samuel, Joossens Jurgen, van der Veken Pieter, Francque Sven, De Bruyn Michelle, Lambeir Anne-Marie, de Man Joris, ....- New ly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bow el syndrome British journal of pharmacology - ISSN 0007-1188 - 175:17(2018), p. 3516-3533 Full text (Publisher's DOI): https://doi.org/10.1111/BPH.14396 To cite this reference: https://hdl.handle.net/10067/1530780151162165141 Institutional repository IRUA NEWLY DEVELOPED SERINE PROTEASE INHIBITORS DECREASE VISCERAL HYPERSENSITIVITY IN A POST-INFLAMMATORY RAT MODEL FOR IRRITABLE BOWEL SYNDROME. Running title: Serine proteases in visceral hypersensitivity Hannah Ceuleers, Nikita Hanning, Jelena Heirbaut, Samuel Van Remoortel, Michelle De bruyn, Jurgen Joossens, Pieter van der Veken, Anne-Marie Lambeir, Sven M Francque, Joris G De Man, Jean-Pierre Timmermans, Koen Augustyns, Ingrid De Meester, Benedicte Y De Winter Hannah Ceuleers, Nikita Hanning, Jelena Heirbaut, Sven Francque, Joris G De Man, Benedicte Y De Winter, Laboratory of Experimental Medicine and Pediatrics, Division of Gastroenterology, University of Antwerp, Antwerp, Belgium. Samuel Van Remoortel, Jean-Pierre Timmermans, Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium. Jurgen Joossens, Pieter van der Veken, Koen Augustyns, Laboratory of Medicinal Chemistry, University of Antwerp, Antwerp, Belgium. Sven Francque, Antwerp University Hospital, Antwerp, Belgium. Michelle De bruyn, Anne-Marie Lambeir, Ingrid De Meester, Laboratory of Medical Biochemistry, University of Antwerp, Antwerp, Belgium.
    [Show full text]
  • Huil36g 169 Data Sheet
    Growth Factor Data Sheet GoldBio growth factors are manufactured for RESEARCH USE ONLY and cannot be sold for human consumption! Interleukin-36G (IL36G) is a pro-inflammatory cytokine that plays an important role in the pathophysiology of several diseases. IL36A, IL36B and IL36G; (formerly IL1F6, IL1F8, and IL1F9) are IL1 family members that signal through the IL1 receptor family members IL1Rrp2 (IL1RL2) and IL1RAcP. IL36B is secreted when transfected into 293-T cells and could constitute part of an independent signaling system analogous to that of IL1A and IL1B receptor agonist and interleukin-1 receptor type I (IL1R1). Furthermore, IL36G also can function as an agonist of NFκB activation through the orphan IL1- receptor-related protein 2. Recombinant human IL36G is synthesized as a protein that contains no signal sequence, no prosegment and no potential N-linked glycosylation site.There is a 53% amino acid homology between human and mouse IL36G. IL36G also has a 25-55% amino acid homology with IL36G and IL1RN, IL1B, IL36RN, IL36A, IL37, IL36B and IL1F10. Catalog Number 1110-36E Product Name IL36G (IL-36 gamma), Human (169 a.a.) Recombinant Human Interleukin-36γ IL36G, IL36γ Interleukin 1 Homolog 1 (IL1H1) Interleukin 1-Related Protein 2 (IL1RP2) Interleukin 1 Family, Member 9 (IL1F9) Source Escherichia coli MW 18.7 kDa (169 amino acids) Sequence MRGTPGDADG GGRAVYQSMC KPITGTINDL NQQVWTLQGQ NLVAVPRSDS VTPVTVAVIT CKYPEALEQG RGDPIYLGIQ NPEMCLYCEK VGEQPTLQLK EQKIMDLYGQ PEPVKPFLFY RAKTGRTSTL ESVAFPDWFI ASSKRDQPII LTSELGKSYN TAFELNIND Accession Number Q9NZH8 Purity >95% by SDS-PAGE and HPLC analyses Biological Activity Fully biologically active when compared to standard. The specific activity is determined by its binding ability in a functional ELISA.
    [Show full text]
  • Genetic Determinants of Circulating Interleukin-1 Receptor Antagonist Levels and Their Association with Glycemic Traits
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Trepo - Institutional Repository of Tampere University GENETIC DETERMINANTS OF CIRCULATING INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS AND THEIR ASSOCIATION WITH GLYCEMIC TRAITS Marja-Liisa Nuotio Syventävien opintojen kirjallinen työ Tampereen yliopisto Lääketieteen yksikkö Tammikuu 2015 Tampereen yliopisto Lääketieteen yksikkö NUOTIO MARJA-LIISA: GENETIC DETERMINANTS OF CIRCULATING INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS AND THEIR ASSOCIATION WITH GLYCEMIC TRAITS Kirjallinen työ, 57 s. Ohjaaja: professori Mika Kähönen Tammikuu 2015 Avainsanat: sytokiinit, insuliiniresistenssi, tyypin 2 diabetes, tulehdus, glukoosimetabolia, genominlaajuinen assosiaatioanalyysi (GWAS) Tulehdusta välittäviin sytokiineihin kuuluvan interleukiini 1β (IL-1β):n kohonneen systeemisen pitoisuuden on arveltu edesauttavan insuliiniresistenssin kehittymistä ja johtavan haiman β-solujen toimintahäiriöihin. IL-1β:n sisäsyntyisellä vastavaikuttajalla, interleukiini 1 reseptoriantagonistilla (IL-1RA), on puolestaan esitetty olevan suojaava rooli mainittujen fenotyyppien kehittymisessä päinvastaisten vaikutustensa ansiosta. IL-1RA:n suojaavan roolin havainnollistamiseksi työssä Genetic determinants of circulating interleukin-1 receptor antagonist levels and their association with glycemic traits tunnistettiin veren IL-1RA- pitoisuuteen assosioituvia geneettisiä variantteja, minkä jälkeen selvitettiin näiden yhteyttä glukoosi- ja insuliinimetaboliaan liittyvien muuttujien-, sekä
    [Show full text]
  • Interleukin (IL)17A, F and AF in Inflammation: a Study in Collageninduced Arthritis and Rheumatoid Arthritis
    bs_bs_banner Clinical and Experimental Immunology ORIGINAL ARTICLE doi:10.1111/cei.12376 Interleukin (IL)-17A, F and AF in inflammation: a study in collagen-induced arthritis and rheumatoid arthritis S. Sarkar,* S. Justa,* M. Brucks,* Summary J. Endres,† D. A. Fox,† X. Zhou,* Interleukin (IL)-17 plays a critical role in inflammation. Most studies to date F. Alnaimat,* B. Whitaker,‡ have elucidated the inflammatory role of IL-17A, often referred to as IL-17. J. C. Wheeler,‡ B. H. Jones§ and IL-17F is a member of the IL-17 family bearing 50% homology to IL-17A S. R. Bommireddy* and can also be present as heterodimer IL-17AF. This study elucidates the *Section of Rheumatology, Department of Medicine, and the Arizona Arthritis Center, distribution and contribution of IL-17A, F and AF in inflammatory arthritis. University of Arizona, Tucson, AZ, †Divison of Neutralizing antibody to IL-17A alone or IL-17F alone or in combination Rheumatology, Department of Internal Medicine, was utilized in the mouse collagen-induced arthritis (CIA) model to eluci- University of Michigan, Ann Arbor, MI, and date the contribution of each subtype in mediating inflammation. IL-17A, F ‡Biologics Research and §Immunology Discovery and AF were all increased during inflammatory arthritis. Neutralization of Research, Janssen Research and Development, IL-17A reduced the severity of arthritis, neutralization of IL-17A+IL-17F had Spring House, PA, USA the same effect as neutralizing IL-17A, while neutralization of IL-17F had no effect. Moreover, significantly higher levels of IL-17A and IL-17F were detected in peripheral blood mononuclear cells (PBMC) from patients with rheumatoid arthritis (RA) in comparison to patients with osteoarthritis (OA).
    [Show full text]
  • Interleukin 2 Medical Intensive Care Unit (4MICU)
    Interleukin 2 Medical Intensive Care Unit (4MICU) Ronald Reagan UCLA Medical Center 757 Westwood Plaza Los Angeles, CA 90095 Main Phone: (310) 267-7441 Fax: (310) 267-3785 About Our Unit The Medical Intensive Care Unit (MICU) cares Quick for critically ill patients in an intensive care Reference Guide environment, with nursing staff specially trained in the administration of Interleukin 2 therapy. Unit Director / Manager Mark Flitcraft, RN, MSN One registered nurse (RN) is assigned to take (310) 267-9529 care of a maximum of two patients. Our Medical Clinical Nurse Specialist Intensive Care Unit patient rooms are designed Yuhan Kao, RN, MSN, CNS (310) 267-7465 to allow nurses constant visual contact with their patients. As a safety precaution, the Medical Assistant Manager Sherry Xu, RN, BA, CCRN Intensive Care Unit is a closed unit and requires (310) 267-7485 permission to enter by intercom. Clinical Case Manager Each private-patient-care room contains the Connie Lefevre (310) 267-9740 most advanced intensive-care equipment available, including cardiac-monitoring and Clinical Social Worker Codie Lieto emergency-response equipment. The curtains in (310) 267-9741 the room will usually be drawn to keep your room Charge Nurse On-Duty more private. (310) 267-7480 or (310) 267-7482 A brief tour is available on weekdays for patients and visitors interested in walking through the unit Patient Affairs (310) 267-9113 and meeting the staff before arrival. To arrange for a tour, please call the nurse manager at Respiratory Supervisor (310) 267-9529. Orna Molayeme, MA, RCP, RRT, NPS (310) 267-8921 UCLAHEALTH.ORG 1-800-UCLA-MD1 (1-800-825-2631) About Our Unit During Your Stay Quick The Medical Team Reference Guide During each shift, you will be assigned a registered nurse (RN) and a clinical care partner (CCP).
    [Show full text]
  • An Ontogenetic Switch Drives the Positive and Negative Selection of B Cells
    An ontogenetic switch drives the positive and negative selection of B cells Xijin Xua, Mukta Deobagkar-Lelea, Katherine R. Bulla, Tanya L. Crockforda, Adam J. Meadb, Adam P. Cribbsc, David Simsc, Consuelo Anzilottia, and Richard J. Cornalla,1 aMedical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, OX3 9DS Oxford, United Kingdom; bMedical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, OX3 9DS Oxford, United Kingdom; and cMedical Research Council, Weatherall Institute of Molecular Medicine, Centre for Computational Biology, Weatherall Institute of Molecular Medicine, University of Oxford, OX3 9DS Oxford, United Kingdom Edited by Michael Reth, University of Freiburg, Freiburg, Germany, and approved January 6, 2020 (received for review September 3, 2019) + Developing B cells can be positively or negatively selected by self- BM HSCs increased CD5 B-1a B cell development (15), while antigens, but the mechanisms that determine these outcomes are expression of let-7b in FL pro-B cells blocked the development of incompletely understood. Here, we show that a B cell intrinsic B-1 B cells (17). These findings support the notion of hard-wired switch between positive and negative selection during ontogeny differences during ontogeny, but possibly downstream of the HSC is determined by a change from Lin28b to let-7 gene expression. commitment stage. Ectopic expression of a Lin28b transgene in murine B cells restored Several lines of evidence also suggest that B-1 B cells can un- the positive selection of autoreactive B-1 B cells by self-antigen in dergo positive selection, which is linked to their B cell receptor adult bone marrow.
    [Show full text]